Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 50 citing articles:

Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge
Daniele Focosi, Rodrigo Quiroga, Scott A. McConnell, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2264-2264
Open Access | Times Cited: 114
Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies
Nur Zawanah Zabidi, Hern Liang Liew, Isra Ahmad Farouk, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 944-944
Open Access | Times Cited: 56
A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19)
Kristin Widyasari, Jin Nam Kim
Antibodies (2023) Vol. 12, Iss. 1, pp. 5-5
Open Access | Times Cited: 24
An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2
Daniele Focosi, Massimo Franchini, Arturo Casadevall, et al.
Clinical Microbiology and Infection (2024) Vol. 30, Iss. 8, pp. 999-1006
Closed Access | Times Cited: 9
Adaptive evolution of SARS-CoV-2 during a persistent infection for 521 days in an immunocompromised patient
Hanno Schmidt, Luca A. Schick, Jürgen Podlech, et al.
npj Genomic Medicine (2025) Vol. 10, Iss. 1
Open Access
Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience
Karolina Akinosoglou, Emmanouil-Angelos Rigopoulos, Georgia Kaiafa, et al.
Viruses (2022) Vol. 15, Iss. 1, pp. 118-118
Open Access | Times Cited: 29
The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2
Letian Fang, Jie Xu, Yue Zhao, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 13
Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
Mingtao Liu, Hui Gan, Zhiman Liang, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 11
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
Michael G. Ison, Debra F. Weinstein, Marta Dobryanska, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 7
Open Access | Times Cited: 11
SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments
Xirui Zhang, Hao Yuan, Zipeng Yang, et al.
Vaccines (2022) Vol. 10, Iss. 12, pp. 2145-2145
Open Access | Times Cited: 19
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine
Giuseppe A. Palumbo, Daniela Cambria, Enrico La Spina, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 10
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence
Irma Convertino, Sara Ferraro, Emiliano Cappello, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 3, pp. 231-245
Closed Access | Times Cited: 9
Allogeneic hematopoietic stem cell transplantation in the COVID-19 era
Jonathan Bordat, Sébastien Maury, Mathieu Leclerc
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 9
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies
Patrick Reimann, Verena Petzer, Axel Mündlein, et al.
Annals of Hematology (2024) Vol. 103, Iss. 6, pp. 2123-2131
Closed Access | Times Cited: 2
A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors
Desh Deepak Singh, Ihn Han, Eun Ha Choi, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 1, pp. 400-433
Open Access | Times Cited: 6
Impact of Treatment with Anti-CD20 Monoclonal Antibody on the Production of Neutralizing Antibody Against Anti–SARS-CoV-2 Vaccination in Mature B-Cell Neoplasms
Akio Onishi, Yayoi Matsumura‐Kimoto, Shinsuke Mizutani, et al.
Infection and Drug Resistance (2023) Vol. Volume 16, pp. 509-519
Open Access | Times Cited: 6
Respiratory delivery of passive immunotherapies for SARS-CoV-2 prophylaxis and therapy
Daniele Focosi, Fabrizio Maggi
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 6
A Review of Hematological Complications and Treatment in COVID-19
Armand N. Yazdani, Arian Abdi, Prathosh Velpuri, et al.
Hematology Reports (2023) Vol. 15, Iss. 4, pp. 562-577
Open Access | Times Cited: 6
Vaccine Based on Recombinant Fusion Protein Combining Hepatitis B Virus PreS with SARS-CoV-2 Wild-Type- and Omicron-Derived Receptor Binding Domain Strongly Induces Omicron-Neutralizing Antibodies in a Murine Model
Pia Gattinger, Bernhard Kratzer, Al Nasar Ahmed Sehgal, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 229-229
Open Access | Times Cited: 1
Vaccine Based on Recombinant Fusion Protein Combining HBV PreS with SARS-CoV-2 Wild-Type- and Omicron-Derived RBD Strongly Induces Omicron-Neutralizing Antibodies
Pia Gattinger, Bernhard Kratzer, Al Nasar Ahmed Sehgal, et al.
(2024)
Open Access | Times Cited: 1
Prevention and treatment strategies for kidney transplant recipients in the context of long-term existence of COVID-19
Zeyuan Zheng, Huimin Sun, Xiao Hu, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 1
Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study
Cesare Ernesto Maria Gruber, Fabio Giovanni Tucci, Emanuela Giombini, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 5
Open Access | Times Cited: 1
Preclinical in vivo assessment of the activity of AZD7442 anti-SARS-CoV-2 monoclonal antibodies against Omicron sublineages
Jean‐Sélim Driouich, Maxime Cochin, Guillaume Lingas, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 116988-116988
Open Access | Times Cited: 1
Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis
Saeed Khorramnia, Zia Navidi, Amirhossein Orandi, et al.
Deleted Journal (2024) Vol. 38, Iss. 2, pp. 136-144
Open Access | Times Cited: 1
Prophylactic and early outpatient treatment of COVID-19 in patients with kidney disease: considerations from the Immunonephrology Working Group of the European Renal Association (ERA-IWG)
Marc Hilhorst, Fréderike J. Bemelman, Annette Bruchfeld, et al.
Nephrology Dialysis Transplantation (2023) Vol. 38, Iss. 8, pp. 1807-1816
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top